
Tricida TCDA
Quartalsbericht 2022-Q3
hinzugefügt 14.11.2022
Tricida Gesamtverbindlichkeiten 2011-2025 | TCDA
Gesamtverbindlichkeiten Jährlich Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 168 M | 243 M | 108 M | 53.3 M | 11.4 M | 75.3 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 243 M | 11.4 M | 110 M |
Gesamtverbindlichkeiten Vierteljährlich Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 230 M | 226 M | 231 M | 168 M | 163 M | 160 M | 174 M | 243 M | 243 M | 243 M | 243 M | 108 M | 108 M | 108 M | 108 M | 53.3 M | 53.3 M | 53.3 M | 53.3 M | 11.5 M | 11.5 M | 11.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 243 M | 11.5 M | 136 M |
Gesamtverbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
430 M | $ 1.21 | -7.63 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
10.2 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
218 M | $ 2.67 | -2.55 % | $ 1.44 B | ||
|
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | ||
|
Aurora Cannabis
ACB
|
244 M | $ 4.47 | -2.08 % | $ 86.3 M | ||
|
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | ||
|
Emergent BioSolutions
EBS
|
1.17 B | $ 12.36 | -2.37 % | $ 633 M | ||
|
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | $ 21.6 | 0.07 % | $ 2.06 B | ||
|
Evolus
EOLS
|
227 M | $ 6.88 | 0.36 % | $ 427 M | ||
|
Harrow Health
HROW
|
242 M | $ 50.08 | -0.16 % | $ 1.63 B | ||
|
China Pharma Holdings
CPHI
|
7.14 M | $ 1.29 | -1.56 % | $ 22.5 M | ||
|
Organogenesis Holdings
ORGO
|
113 M | $ 5.36 | -8.71 % | $ 706 M | ||
|
OrganiGram Holdings
OGI
|
102 M | $ 1.8 | 1.99 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
27.4 B | $ 7.19 | -0.07 % | $ 2.62 B | ||
|
Pacira BioSciences
PCRX
|
775 M | $ 26.48 | 1.77 % | $ 1.22 B | ||
|
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
36.5 M | - | - | $ 193 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
53 M | $ 4.11 | -2.14 % | $ 57.8 M | ||
|
Rockwell Medical
RMTI
|
30.9 M | $ 0.87 | 7.18 % | $ 20.3 M | ||
|
Solid Biosciences
SLDB
|
51.4 M | $ 5.83 | -1.19 % | $ 238 M | ||
|
Sundial Growers
SNDL
|
216 M | $ 1.75 | -1.13 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 3.63 | -0.41 % | $ 4.5 M | ||
|
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | ||
|
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | ||
|
Jupiter Wellness
JUPW
|
9.51 M | - | - | $ 33.6 M | ||
|
Veru
VERU
|
28.1 M | $ 2.37 | 1.28 % | $ 320 M | ||
|
Perrigo Company plc
PRGO
|
5.33 B | $ 13.87 | 0.95 % | $ 1.91 B | ||
|
ProPhase Labs
PRPH
|
24 M | $ 0.51 | -16.94 % | $ 8.08 M | ||
|
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.5 | -2.21 % | $ 135 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 1.69 | 3.68 % | $ 7.29 M | ||
|
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
148 M | $ 9.92 | 0.22 % | $ 705 M | ||
|
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
55.4 M | $ 0.58 | -1.87 % | $ 27.8 M | ||
|
Tilray
TLRY
|
977 M | $ 9.6 | -5.43 % | $ 5.93 B | ||
|
TherapeuticsMD
TXMD
|
14 M | $ 1.72 | 0.88 % | $ 18 M | ||
|
Viatris
VTRS
|
28.9 B | $ 12.33 | 0.69 % | $ 14.9 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M |